HC Wainwright Has Positive Estimate for ACHV FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Achieve to ($1.28) from ($1.35), reaffirmed a "Buy" rating and a $12 price target, and projects the company turning profitable by FY2028 with rising EPS through FY2030.
• Major near‑term catalysts include a PDUFA date (June 20, 2026) for cytisinicline and a planned Phase 3 vaping‑cessation trial (ORCA‑V2) in 1H 2026, but the company remains unprofitable (Q4 EPS miss) with cash‑burn and dilution risks until regulatory approval and commercial revenue arrive.
• Achieve has a consensus rating of "Moderate Buy" with an average target of $15.50; the stock trades near $2.89 with a market cap of about $154 million, a 1‑year range of $1.84–$6.03, and roughly 33.5% institutional ownership.

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings estimates for shares of Achieve Life Sciences in a research report issued on Wednesday, March 25th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn ($1.28) per share for the year, up from their prior estimate of ($1.35). HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Achieve Life Sciences' current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences' FY2027 earnings at ($1.24) EPS, FY2028 earnings at $0.36 EPS, FY2029 earnings at $1.52 EPS and FY2030 earnings at $2.31 EPS.

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $15.50.

Achieve Life Sciences Price Performance

ACHV stock opened at $2.89 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.14 and a current ratio of 4.39. Achieve Life Sciences has a 1 year low of $1.84 and a 1 year high of $6.03. The firm has a market cap of $153.83 million, a P/E ratio of -2.22 and a beta of 1.81. The stock has a 50-day simple moving average of $4.38 and a 200-day simple moving average of $4.29.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Institutional Trading of Achieve Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of ACHV. Franklin Resources Inc. lifted its stake in shares of Achieve Life Sciences by 81.3% in the second quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company's stock worth $10,077,000 after acquiring an additional 2,000,079 shares in the last quarter. Vanguard Group Inc. increased its holdings in Achieve Life Sciences by 14.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company's stock worth $7,755,000 after purchasing an additional 311,925 shares during the last quarter. Millennium Management LLC increased its holdings in Achieve Life Sciences by 472.3% during the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company's stock worth $6,755,000 after purchasing an additional 1,121,614 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at approximately $2,652,000. Finally, Marshall Wace LLP boosted its stake in shares of Achieve Life Sciences by 31.5% during the 4th quarter. Marshall Wace LLP now owns 1,019,281 shares of the biopharmaceutical company's stock valued at $5,066,000 after buying an additional 244,428 shares during the last quarter. 33.52% of the stock is owned by hedge funds and other institutional investors.

Achieve Life Sciences News Roundup

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reaffirmed a "Buy" rating and set a $12 price target, raising visibility on upside if cytisinicline gains FDA approval and commercial traction; the firm also published short‑term EPS forecasts tied to ongoing development. HC Wainwright Buy Rating
• Positive Sentiment: Unusually large retail/institutional call option purchases were reported, signaling speculative bullish positioning that can amplify near‑term upside and volatility. Investors Purchase Call Options
• Positive Sentiment: Publication in Nicotine & Tobacco Research linked cytisinicline’s receptor selectivity to low nausea and favorable tolerability — data that supports the drug’s safety profile and could aid regulatory review and prescriber adoption. GlobeNewswire Publication
• Positive Sentiment: Analyst/industry commentary highlights an upcoming FDA PDUFA date (June 20, 2026) for cytisinicline and plans to start a Phase 3 vaping‑cessation trial (ORCA‑V2) in 1H 2026 — both are key milestones that could create major value inflection points if positive. Seeking Alpha PDUFA / Vaping Expansion
• Neutral Sentiment: Company Q4 2025 earnings call and accompanying summaries reviewed program timelines, manufacturing partnerships and commercialization planning — useful for modeling but no new regulatory decision was announced on the call. Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 2025 results showed a slight EPS miss (reported -$0.28 vs. consensus -$0.27) and the company remains unprofitable with negative forward EPS consensus; until regulatory approval and commercial revenue arrive, cash burn and dilution risk remain headwinds. Q4 2025 Earnings Call Transcript

About Achieve Life Sciences

Achieve Life Sciences, Inc NASDAQ: ACHV is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.